Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015828 | 1.00 | MAPT (0.36) | MAPTKDM4EMEN1GAAKMT2A | |
| SCHEMBL31587724 | 1.00 | MAPT (0.36) | MAPTKDM4EMEN1GAAKMT2A | |
| SCHEMBL1014891 | 0.93 | MAPT (0.35) | MAPT | |
| SCHEMBL1016151 | 0.93 | CES2 (0.39) | MAPT | |
| SCHEMBL1016150 | 0.93 | CES2 (0.39) | MAPT | |
| SCHEMBL1014889 | 0.93 | MAPT (0.35) | MAPT | |
| SCHEMBL1014910 | 0.91 | CES2 (0.42) | MAPT | |
| SCHEMBL1014911 | 0.91 | CES2 (0.42) | MAPT | |
| SCHEMBL21960394 | 0.89 | RECQL (0.39) | MAPTRECQL | |
| SCHEMBL1015324 | 0.82 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-117986249-A | Pyrazole derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4210694-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| WO-2022056051-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-1718620-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| CN-1225466-C | Sodium-hydrogen exchangertype 1 inhibitor (NHE-1) | PFIZER PROD INC (US) | 2005-11-02 | — | — | CN | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005080350-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-6852733-B2 | Sodium-hydrogen exchanger type 1 inhibitor | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| CN-1426404-A | Sodium-hydrogen exchanger type I (NHE-1) inhibitors | PFIZER PROD INC (US) | 2003-06-25 | — | — | CN | disclosed |
| EP-1276737-A1 | SODIUM-HYDROGEN EXCHANGER TYPE 1 INHIBITOR (NHE-1) | Pfizer Products Inc. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051634-A1 | Sodium-hydrogen exchanger type 1 inhibitor | CHEN WEICHAO G (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001083470-A1 | SODIUM-HYDROGEN EXCHANGER TYPE 1 INHIBITOR (NHE-1) | PFIZER PRODUCTS INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MAPT 2953/4885KDM4E 738/4885MEN1 686/4885 |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | MAPT 781/4885KDM4E 1074/4885MEN1 1113/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MAPT 2953/4885KDM4E 738/4885MEN1 686/4885 |
| US-20010051634-A1 | Sodium-hydrogen exchanger type 1 inhibitor | NHERF1, SLC9A1, SLC9A2 | MAPT 4112/4885KDM4E 4127/4885MEN1 2795/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | MAPT 3851/4885KDM4E 4437/4885MEN1 4656/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MAPT 2953/4885KDM4E 738/4885MEN1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.